Tirzepatide clinical trials, in English

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to measure the safety and how well it works of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs.

NCT06143956 · Official ClinicalTrials.gov record · Eli Lilly and Company

The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer

NCT06759701 · Official ClinicalTrials.gov record · M.D. Anderson Cancer Center

This study wants to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity.

NCT06842186 · Official ClinicalTrials.gov record · Wave Life Sciences USA, Inc.

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.

NCT06857942 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with dummy treatment (placebo) in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

NCT06897475 · Official ClinicalTrials.gov record · Eli Lilly and Company

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and dummy treatment (placebo), leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

NCT06937086 · Official ClinicalTrials.gov record · Eli Lilly and Company

The main purpose of this study is to measure the how well it works and safety of mirikizumab and dummy treatment (placebo) compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.

NCT06937099 · Official ClinicalTrials.gov record · Eli Lilly and Company

LCCC2415 examines the antiproliferative effect of tirzepatide on the endometrium of endometrial cancer (EC). This is a pre-operative window clinical study.

NCT07065552 · Official ClinicalTrials.gov record · UNC Lineberger Comprehensive Cancer Center

This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are pursuing fertility sparing. GLP-1RA are a class of medications that mimic the natural hormone glucagon-like peptide-1.

NCT07107334 · Official ClinicalTrials.gov record · University of Florida

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO.

NCT07165028 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.

NCT07218445 · Official ClinicalTrials.gov record · Mayo Clinic

This study wants to: * measure the safety, tolerability, how well it works, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * measure the safety, tolerability, how well it works, PK, and PD of multiple doses of ALN-2232 in patients with obesity * measure the safety, tolerability, how well it works, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

NCT07463846 · Official ClinicalTrials.gov record · Alnylam Pharmaceuticals

This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing protein 3 (PNPLA3), a protein that liver cells make, which may help decrease liver fat if there is an abnormal PNPLA3 protein.

NCT07527910 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

Background: Glucagon-like peptide 1 (GLP-1) agonist drugs are used to treat diabetes and aid weight loss. They may also help reduce cravings for drugs and alcohol.

NCT07559500 · Official ClinicalTrials.gov record · National Institute on Alcohol Abuse and Alcoholism (NIAAA)

The goal of this clinical trial is to determine whether a flexible, symptom-guided titration strategy for tirzepatide can help adults with obesity without diabetes stay on treatment longer, while maintaining weight-loss effectiveness. The main questions it aims to answer are: * Does flexible, symptom-guided titration increase time on treatment (delay treatment discontinuation) compared with standard per-label titration over 76 weeks?

NCT07574723 · Official ClinicalTrials.gov record · Dasman Diabetes Institute

This multicenter randomly assigned controlled trial will evaluate whether an AI-assisted intensive lifestyle intervention can improve weight and glycemic management in adults with obesity and newly diagnosed type 2 diabetes, compared with tirzepatide treatment and standard lifestyle management. Eligible you would be adults aged 18 to 65 years with a body mass index of 28 to less than 40 kg/m² and newly diagnosed type 2 diabetes who have not used glucose-lowering medications in the past 3 months.

NCT07697391 · Official ClinicalTrials.gov record · The First Affiliated Hospital of Anhui Medical University

The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults. The main questions it aims to answer are: * Does tirzepatide improve the symptoms and signs of active CCCA?

NCT07734870 · Official ClinicalTrials.gov record · Johns Hopkins University

Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is associated with a reduced metabolic rate at rest and during physical activity, increased insulin resistance, limited mobility, and potential long-term adverse effects.

NCT07777575 · Official ClinicalTrials.gov record · Technical University of Munich

The proposed study seeks to address a critical gap in the management of lorlatinib-induced metabolic derangements, particularly rapid weight gain, which can adversely affect treatment adherence, dosing and ultimately patient outcomes. In this study patients with non-small cell lung cancer (NSCLC) receiving lorlatinib treatment will receive tirzepatide, a dual GIP/GLP-1 receptor agonist with demonstrated how well it works in weight reduction and metabolic improvement.

NCT07782359 · Official ClinicalTrials.gov record · University of Chicago

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to measure the how well it works, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less than 12 years of age, with obesity. Participation in the study will last about 104 weeks.

NCT07817875 · Official ClinicalTrials.gov record · Eli Lilly and Company

This is a phase 2, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, parallel-group trial evaluating the tolerability, safety, and preliminary how well it works of tirzepatide for the treatment of individuals with moderate or severe methamphetamine use disorder (MtUD). The central hypothesis of the proposed research is that tirzepatide is a safe and potentially efficacious treatment of MtUD.

NCT07825857 · Official ClinicalTrials.gov record · University of Texas Southwestern Medical Center

Researchers want to understand what happens to muscle and fat in the body after adults with obesity and/or type 2 diabetes start taking a GLP-1 receptor agonist medication (GLP-1RA), a type of drug already approved and commonly prescribed for weight loss and blood sugar control. No experimental medication will be given.

NCT07835360 · Official ClinicalTrials.gov record · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

This randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to measure the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection

NCT07842640 · Official ClinicalTrials.gov record · Ascletis Pharma (China) Co., Limited

This study wants to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.

NCT07845500 · Official ClinicalTrials.gov record · Pfizer

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity.

NCT07858864 · Official ClinicalTrials.gov record · Istanbul Saglik Bilimleri University

This single-center randomly assigned comparative study is designed to compare the effectiveness of tirzepatide and transcutaneous low-frequency auricular vagus nerve stimulation in adults with class I obesity and without chronic non-communicable diseases. The study focuses on changes in body weight, anthropometric indices, epicardial and visceral adipose tissue, body composition, behavioral factors, skeletal muscle characteristics, and cardiac structure and function.

NCT07866183 · Official ClinicalTrials.gov record · National Medical Research Center for Therapy and Preventive Medicine

The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get tirzepatide and zenagamtide.

NCT07868354 · Official ClinicalTrials.gov record · Novo Nordisk A/S

This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic. The study will enroll young adults (18-39 years) with soft tissue or bone sarcoma who are overweight (body-mass index (BMI) 25-29.9 kg/m² with ≥1 cardiovascular risk factor) or obese (body-mass index (BMI) ≥30 kg/m²), have completed Dox-based chemotherapy (≥300 mg/m²) approximately three months prior to enrollment, and have preserved LVEF (≥50%) preenrollment.

NCT07874828 · Official ClinicalTrials.gov record · M.D. Anderson Cancer Center

This study wants to investigate the how well it works and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 2 years.

NCT07881458 · Official ClinicalTrials.gov record · Eli Lilly and Company

The goal of this clinical trial is to determine if there are differences in the effect of 12 weeks of tirzepatide versus semaglutide on energy balance in adults with obesity and without known diabetes. The main questions it aims to answer are: \- Does tirzepatide have a greater effect on energy expenditure or energy extraction than semaglutide?

NCT07900074 · Official ClinicalTrials.gov record · McMaster University

This prospective watch-and-measure (no experimental treatment required) study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included.

NCT07924618 · Official ClinicalTrials.gov record · Istanbul University

The goal of this watch-and-measure (no experimental treatment required) study is to learn how treatment with incretins, such as semaglutide and tirzepatide, affects muscle mass, muscle strength, and physical function in people with overweight or obesity. The main questions this study aims to answer are: * What is the composition of weight loss during incretin treatment?

NCT07929831 · Official ClinicalTrials.gov record · Radboud University Medical Center